1. ALLA AKTIER
  2. NYHETER
  3. INITIATOR PHARMA

Initiator Pharma

Nyheter Initiator Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Finalization of share buyback program in Initiator Pharma

MARKN.

Initiator Pharma A/S (“Initiator” or the “Company”) has today finalized the share buyback that was announced on 14 October 2024.

Today, Initiator has finalized the buyback of shares that was announced on 14 October 2024. In connection with the share buyback, the Company has repurchased a total of 23,000 shares ("Treasury Shares"), through Nasdaq First North Growth Market. The average price was SEK 7.24 (DKK 4.71).
 
Initiator has sold the Treasury Shares to certain members of the Board of Directors as matching shares under the LTI2023-program. Each share was sold at a price of DKK 0.105 per share corresponding to par value.
 
The aggregate gross proceeds from the sale of treasury shares are DKK 2,415.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine and IP2018 – and two preclinical assets. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Finalization of share buyback program in Initiator Pharma

Datum 2024-10-25, kl 08:30
Källa MFN
Bifogade filer
Finalization of share buyback program in Initiator Pharma